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Abstract
Prevalence of hepatitis C virus (HCV) infection is relatively low in children. However, 
seroprevalence rates of 10–20% have been reported among children who received 
repeated transfusion. The development and the severity of liver fibrosis are strongly 
related to the extent of the liver iron overload and to the presence of chronic hepati-
tis C (CHC). In CHC, liver iron overload has been suggested as a negative prognos-
tic factor exacerbating inflammation with subsequent progression of liver fibrosis and 
decrease in antiviral therapy effectiveness. CHC may be suspected based on medical 
history or accidentally discovered abnormal liver functions. Hepatitis C is diagnosed 
by positive serology for viral antibodies and confirmed by polymerase chain reaction 
(PCR) to detect virus RNA. The treatment of HCV infection in children was difficult due 
to the limitations of pegylated interferon-α and ribavirin. In 2017, FDA approved the 
first direct-acting antiviral agents (DAAs) for children including ledipasvir/sofosbuvir 
in the adult dose, 90/400 mg, to treat HCV in children and adolescents aged 12 years and 
older or weighing at least 35 kg. Similarly, giving half the adult fixed-dose of ledipas-
vir/sofosbuvir, 45/200 mg, to children aged 6–11 years is still under clinical trials with 
promising results.
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1. Introduction
The prevalence of hepatitis C virus (HCV) infection is relatively high in thalassemic chil-
dren. The development and the severity of liver fibrosis in those children are strongly related 
to the extent of the liver iron overload and to the presence of chronic hepatitis C. Chronic 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
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hepatitis C (CHC) in most infected patients lead to the development of liver fibrosis, cirrho-
sis, portal hypertension and hepatocellular carcinoma. Therefore, all persons with positive 
anti-HCV antibody tests must undergo additional testing for the presence of the HCV itself 
using polymerase chain reaction (PCR). Combined pegylated interferon-α and ribavirin with 
its limitations and serious complications remained the standard therapy for pediatric HCV 
infections until early 2017. Fortunately, the recent development of the direct-acting antiviral 
agents (DAAs) and the FDA approval of ledipasvir/sofosbuvir in the adult dose, to treat HCV 
in children and adolescents aged 12 years and older or weighing at least 35 kilograms has 
revolutionized the treatment of HCV infection.
2. Background
The prevalence of HCV is increasing and estimates of the future burden of CHC predict at 
least a threefold rise in chronic liver disease and cirrhosis by the year 2020 [1].
3. Epidemiology of hepatitis C
About 3% of the worldwide population is infected by HCV with a significant racial difference. 
Males are more commonly affected than females due to frequent exposure to intravenous drug 
and alcohol abuse. Females are frequently infected from blood product transfusions [2]. The 
most affected regions are Eastern Mediterranean and European Regions [3]. Egypt has possibly 
the highest HCV prevalence in the world where 10–20% of the general population is infected 
[3]. The prevalence of HCV in North Egypt and South Egypt is 15.8 and 6.7%, respectively [4].
The prevalence of HCV infection is relatively low in children. Asymptomatic HCV is detect-
able in 2.02% of Egyptian children [5]. However, seroprevalence rates of 10–20% have been 
reported among children who received blood products for conditions such as thalassemia or 
hemophilia or those with a variety of other potential exposures such as malignancy, hemo-
dialysis, extracorporeal membrane oxygen, or surgery for different reasons [6, 7]. A study in 
Mid-Delta, Egypt, reports 40% of patients with thalassemia are infected with HCV [8].
4. Hepatitis C virus (HCV) and its genotypes
Hepatitis C virus is small, single-stranded, enveloped RNA virus of the flaviviridae family 
[9]. The only natural host is man. Currently, there are six HCV genotypes and many subtypes 
(1a, 1b, 1c, etc.). All HCV genotypes have a common ancestor virus. However, HCV geno-
types 1, 2 and 4 are more prevalent in Central and Western Africa, genotype 5 in South Africa 
and genotypes 3 and 6 in China, South-East Asia and the Indian subcontinent [10]. Genotype 
4 is widespread in East Africa and Egypt [11]. Approximately 90% of Egyptian HCV isolates 
belong to a single subtype, 4a, which responds less successfully to interferon therapy than 
other subtypes [12].
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5. Modes of HCV transmission
The main mode of transmission in children has changed over time. Before 1990, when HCV 
had not been identified, transfusion of blood and blood products and organ transplantation 
were the usual mode of transmission. One of the major routes of transmission is the reuse or 
inadequate sterilization of medical equipment, especially syringes and needles in healthcare 
settings. Currently, perinatal transmission accounts for most of cases [13].
Vertical transmission is almost always confined to women with detectable HCV RNA. The 
rate of vertical transmission is approximately 5%. Mothers with higher titers of HCV RNA 
and those who are HIV positive are more liable to pass the infection to their babies with trans-
mission rates varying from 2 to 12%, according to maternal infectivity. Hepatitis C antibody 
is passively transmitted, and so all infants will have HCV antibody for up to 13–18 months. 
Measurement of HCV RNA is necessary to detect active infection, but it is unreliable before 3 
months of age. Breastfeeding is safe in mothers with low titers of HCV RNA [14]. In children 
with beta thalassemia, the blood transfusion is not the only way of transmission but commu-
nity and environmental factors may play a role [8].
6. Iron overload and hepatitis C virus in patients with thalassemia
Multicenter cross-sectional studies have reported that the development and the severity 
of liver fibrosis are strongly related to the extent of the liver iron overload and to the 
presence of chronic HCV infection [15]. HCV infection is the main risk factor for liver 
fibrosis in transfusion-dependent thalassemia. Excess liver iron is now clearly recognized 
as a cofactor for the development of advanced fibrosis in patients with HCV infection [16]. 
Despite its clinical relevance, thalassemia-associated liver damage has been insufficiently 
characterized [17].
Most of HCV-RNA negative patients with low iron load did not develop liver fibrosis, while 
HCV-RNA positive patients infected with genotype 1 or 4 and iron overload more frequently 
developed advanced fibrosis. Adequate chelation therapy usually prevents the development 
of liver fibrosis in patients free of HCV infection and reduces the risk of developing severe 
fibrosis in thalassemics with chronic hepatitis C (CHC) [15].
7. Relationship between chronic hepatitis C and liver iron 
concentration in thalassemia patients
Hepatitis C virus infection is responsible for 80–90% of post transfusion cases of hepatitis 
in patients who have received blood transfusions (more than 75% of HCV infection become 
chronic and up to 20–30% progress to cirrhosis) [18]. The main causes of liver fibrosis in trans-
fusion-dependent thalassemia major are HCV infection and hepatic iron overload [16].
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Chronic hepatitis in most infected patients lead to the development of liver fibrosis, cirrho-
sis and hepatocellular carcinoma. Patients with HCV have mildly to moderately increased 
hepatic iron concentration and occasionally have severe hepatic iron overload [13]. The 
increased iron stores may be due to release from damaged hepatocytes, to the virus itself or to 
genetic determinants so that the iron can influence the progression of chronic hepatitis C [19].
In patients with CHC, the degree of liver fibrosis and hepatic iron concentration were cor-
related. However, this correlation cannot be translated as a causal relation. It is not clear 
whether this correlation merely reflects the presence of more active disease or iron exacer-
bates chronic HCV-induced damage through activation of hepatic stellate cells (HSC) and 
regeneration of hepatocytes [20].
8. Pathogenesis and clinical consequences of iron overload in 
chronic hepatitis C
Iron overload induces oxidative stress leading to cell membrane damage, DNA instability and 
mutagenesis [21]. Due to these effects, iron can be considered a proinflammatory, profibro-
genic factor and a potential carcinogen [22].
Increased hepatic iron potentiates progression toward liver fibrosis and contributes to poor 
response to interferon therapy [18]. There is evidence that excess iron is known to promote 
oxidative stress and cause direct liver damage and accelerate progression to both micronodu-
lar cirrhosis and hepatocellular carcinoma [23]. Based on the above-mentioned observations, 
iron overload has been suggested as a negative prognostic factor of chronic hepatitis C with 
influence on the increased aminotransferase activity, exacerbation of inflammation, progres-
sion of liver fibrosis and decrease in antiviral therapy effectiveness [24]. Iron accumulation in 
the liver induces oxidative stress which accelerates lipid peroxidation, resulting in destruc-
tion of organelle membrane and cell death via hepatocyte necrosis or/and apoptosis [25]. 
Also, oxidative stress products induce a focal inflammatory reaction which in turn stimulates 
hepatic macrophages and release of profibrogenic cytokines [26]. These mechanisms trigger 
the activation of hepatic stellate cells (HSC) which are major sources of collagen and other 
extracellular matrix elements that gradually accumulate in perisinusoidal spaces of liver 
parenchyma [27]. Longer hepatocyte exposure to excess iron is associated with greater risk of 
progressive fibrosis and development of liver cirrhosis with irreversible nodular reconstruc-
tion of the organ, replacement of the functional liver parenchyma with the connective tissue 
and loss of function [28]. Due to these effects, there is evidence that moderate to severe liver 
iron concentration and chronic HCV infection in thalassemia patients have a potentiating 
effect on hepatic fibrogenesis [29].
9. Symptoms and signs of hepatitis C
Acute HCV infection becomes chronic in 70% of patients, which represents a high rate of 
chronicity for a viral infection. Most patients with CHC and compensated hepatic synthetic 
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functions are usually asymptomatic. They may have nonspecific complaints like fatigue or 
malaise. However, patients with decompensated cirrhosis post HCV infection have the same 
symptoms observed in other patients with decompensated liver diseases.
Manifestations in patients with decompensated liver disease occur merely due to synthetic 
dysfunction and portal hypertension. These include mental status changes (hepatic enceph-
alopathy), ankle edema and abdominal distention (ascites), and hematemesis or melena 
(variceal bleeding). Sometimes, extrahepatic manifestations of HCV are the first symptoms 
observed; most commonly, it involves the joints, muscle and skin [30].
10. Diagnosis of hepatitis C
As most patients of hepatitis C experience no or non-specific symptoms during acute phase, 
they usually do not seek medical advice and diagnosis is rarely made at this phase of the 
disease. The clinical diagnosis of hepatitis C in chronic phase is also challenging as the patient 
may spend decades with compensated liver functions lacking any specific symptoms until 
advanced liver disease develops [31].
Chronic hepatitis C may be suspected clinically on the basis of the medical history. A history 
of unsafe injections as IV drug abuse or inhaled substance usage, such as cocaine, piercings or 
tattoos, sharing toothbrushes or personal sharp objects (e.g. nail scissors or cutters) with HCV 
patient raise the suspicion of HCV infection. Unexplained easy fatigability, with abnormal 
liver enzymes or liver function tests found during routine blood testing may be the clue. Also, 
hepatitis C may be diagnosed as a result of targeted screening; such as screening of blood 
donors or HCV contact tracing [32].
Diagnosis of HCV can never be made on clinical bases only. Serological blood test is the first 
step in diagnosis. The test is used to detect antibodies to HCV. Anti-HCV antibodies can be 
detected in 80% of patients within 15 weeks after exposure, in >90% within 5 months, and in 
>97% by 6 months after exposure and may persist for life even in treated patients. This makes 
the test more valuable to diagnose infection but not to test cure of HCV chronic infection. 
HCV antibody tests have a strong positive predictive value for exposure to HCV but may miss 
patients in early phase who have not yet developed antibodies, or those who have an insuf-
ficient level of antibodies to detect [31, 32].
Immunocompromised individuals infected with HCV may never develop antibodies to the 
virus. So, using HCV antibody test is of no value in screening immuncompromised patients 
for HCV, and they should be screened using a test to detect the virus itself if HCV infection 
is suspected [33].
Anti-HCV antibodies indicate exposure to the virus but cannot determine the presence of 
ongoing infection. So, all persons with positive serology must undergo additional testing to 
confirm the presence of current infection. Molecular nucleic acid testing methods, such as 
polymerase chain reaction (PCR) are used to test the presence of virus RNA in the blood [34]. 
HCV RNA PCR is a quantitative test that has the capacity to detect not only the presence but 
also the amount of virus copies present in the blood which is also known as “viral load”. HCV 
Hepatitis C Virus in Thalassemia
http://dx.doi.org/10.5772/intechopen.76087
81
viral load neither indicate disease severity nor prognosis. It was a predictor of response to 
interferon-based therapy but not important now with the current therapy [33].
Genotype testing was generally recommended before therapy as it was used to determine 
the required length and potential response to interferon-based therapy. This concept was 
changed with the introduction of direct-acting antiviral drugs [35].
11. Treatment of hepatitis C
11.1. Standard PEG interferon/ribavirin (PEG-IFN/RBV) combination therapy
The treatment of HCV infection in children was difficult as few options were available. The 
standard therapy for children aged 3 years and older was combined pegylated interferon 
(PEG-IFN) α-2a or 2b and ribavirin, and the duration of therapy was dependent on HCV 
genotype. This treatment regimen was developed first in adults [36, 37]. Combined pegylated 
interferon-α and ribavirin with its limitations and serious complications remained the stan-
dard therapy for pediatric HCV infections till 2017 [38].
11.2. New direct-acting antiviral agents
In recent years, many direct-acting antiviral agents (DAAs) are under development for treat-
ment of CHC. DAAs reduce the amount of HCV in the body by blocking viral replication 
inhibiting directly one of the several steps of the HCV lifecycle preventing the virus from mul-
tiplying, and in most cases, they cure HCV. DAAs are classified into several categories based 
on their molecular target [39, 40]. The recent development of DAAs has shown promising 
results in clinical trials for use in children and adults and has dramatically increased the rates 
of sustained virological response (SVR) while improving side effect profiles as compared to 
interferon-based treatments [41]. Prior to 2017, new DAAs available for adults have still not 
been approved for treatment in children [37, 38, 41, 42].
Recently (on April 7, 2017), the US Food and Drug Administration (FDA) approved the first 
DAAs for children that included sofosbuvir (Sovaldi) and sofosbuvir/ledipasvir (Harvoni) 
to treat HCV in children and adolescents aged 12 years and older or weighing at least 35 kg. 
These DAAs (Harvoni and Sovaldi) were previously approved to treat HCV in adults. These 
approvals will help change the landscape for HCV treatment by addressing an unmet need 
in children and adolescents [43]. The adult fixed-dose of ledipasvir/sofosbuvir, 90/400 mg, 
resulted in similar plasma exposure of ledipasvir, sofosbuvir and GS-331007 (the inac-
tive metabolite of sofosbuvir) in adolescents as in adults, thus the adult dose was used for 
this age group [44]. Similarly, giving half the adult fixed-dose of ledipasvir/ sofosbuvir, 
45/200 mg, to children ages 6–11 years resulted in comparable plasma exposure of ledipas-
vir, sofobuvir and GS-331007 as in adults, without any severe adverse events or laboratory 
abnormalities [45].
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